Difference Between Fibrinolytic and Antithrombotic Therapy
Fibrinolytic therapy actively dissolves existing blood clots by breaking down fibrin, while antithrombotic therapy prevents new clot formation through anticoagulation (blocking the clotting cascade) or antiplatelet effects (preventing platelet aggregation). 1
Mechanism of Action
Fibrinolytic Agents
- Actively lyse formed clots by converting plasminogen to plasmin, which directly degrades fibrin molecules within existing thrombi 2, 3
- Work by promoting plasmin-mediated fibrin degradation to achieve vessel recanalization 4
- Include agents such as alteplase (tPA), tenecteplase (TNK-tPA), reteplase (rPA), and streptokinase 2
- Provide rapid restoration of blood flow in acute thrombotic emergencies 5
Antithrombotic Agents
Antithrombotic therapy encompasses two distinct categories 6:
Anticoagulants:
- Prevent fibrin formation by inhibiting the coagulation cascade 1
- Include heparin (acts on antithrombin III), warfarin, and direct oral anticoagulants 6
- Do not dissolve existing clots but prevent extension and new thrombus formation 3
Antiplatelet Agents:
- Prevent platelet adhesion and aggregation 6
- Include aspirin, clopidogrel, and GP IIb/IIIa inhibitors 2
- Block platelet-mediated thrombosis pathways 2
Clinical Applications
When Fibrinolytics Are Used
- ST-elevation myocardial infarction (STEMI) when primary PCI cannot be performed within 120 minutes and symptom onset is within 12 hours 2
- Acute ischemic stroke within appropriate time windows 2
- Massive pulmonary embolism with hemodynamic compromise 2
- Catheter-directed therapy for submassive PE, deep vein thrombosis, and acute limb ischemia 4
When Antithrombotics Are Used
- Prevention and treatment of venous thromboembolism (anticoagulants are first-line) 6
- Atrial fibrillation stroke prevention (oral anticoagulants) 2
- Acute coronary syndromes (combination antiplatelet therapy with aspirin and P2Y12 inhibitors) 2
- Post-PCI to prevent stent thrombosis (dual antiplatelet therapy) 2
- Long-term secondary prevention after MI or stroke 2
Critical Contraindications
Fibrinolytic Therapy Absolute Contraindications
- Previous intracranial hemorrhage or stroke of unknown origin 2
- Ischemic stroke within preceding 6 months 2
- Active bleeding or bleeding diathesis 2
- Recent major surgery or trauma within 3 weeks 2
- Suspected aortic dissection 2
- Recent surgery is a strong contraindication due to substantial bleeding risk at surgical sites 2
Key Safety Differences
- Fibrinolytics carry 0.9-1.0% risk of intracranial hemorrhage and 4-13% risk of major non-cerebral bleeding 2
- Antithrombotics have lower bleeding risk profiles, making them suitable for chronic use 6
- In perioperative MI, primary PCI is strongly preferred over fibrinolysis due to bleeding concerns at surgical sites 2
Adjunctive Therapy Considerations
Fibrinolysis Requires Antithrombotic Support
- Aspirin (162-325 mg loading) and clopidogrel must be administered with fibrinolytic therapy for STEMI 2
- Anticoagulation with heparin or other agents is mandatory as adjunctive therapy 2
- This combination reduces reinfarction rates by 30-40% 5
Antithrombotics Are NOT Fibrinolytics
- Fibrinolytic therapy is contraindicated in non-ST-elevation ACS where antithrombotics alone are used 2
- Pooled data showed 9.8% death/MI rate with fibrinolytics versus 6.9% with control in unstable angina 2
- Antithrombotic therapy alone is appropriate for most venous thromboembolism without need for fibrinolysis 2
Common Clinical Pitfall
Do not confuse "clot prevention" with "clot dissolution": Antithrombotic therapy (anticoagulants and antiplatelets) prevents new thrombus formation but does not actively break down existing clots 1, 3. Fibrinolytic therapy actively dissolves formed clots but carries significantly higher bleeding risk and has narrow time windows and specific indications 4, 7. Using the wrong therapy category can result in either inadequate treatment of acute thrombotic emergencies or unnecessary bleeding complications.